ACADIA Pharmaceuticals (ACAD) financial statements
ACADIA Pharmaceuticals reported revenue of $1.1B in fiscal 2025, up 58.1% a year over 9 years.
Net income was $391M and the operating margin 9.8%, against -1574.1% in 2016.
Free cash flow was $105M.
The diluted share count rose 47% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from ACADIA Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17M | $125M | $224M | $339M | $442M | $484M | $517M | $726M | $958M | $1.1B |
| Cost of revenue | $3M | $9M | $12M | $11M | $10M | $19M | $10M | $42M | $82M | $89M |
| Gross profit | $14M | $116M | $211M | $328M | $432M | $473M | $507M | $685M | $876M | $983M |
| Research and development | $99M | $149M | $187M | $240M | $319M | $239M | $362M | $352M | $303M | $329M |
| Selling, general and admin | $186M | $255M | $266M | $326M | $389M | $396M | $369M | $407M | $488M | $549M |
| Operating income | -$273M | -$292M | -$247M | -$247M | -$287M | -$170M | -$224M | -$73M | $231M | $105M |
| Pre-tax income | -$270M | -$288M | -$244M | -$234M | -$281M | -$168M | -$213M | -$51M | $258M | $139M |
| Income tax | $1M | $1M | $1M | $876,000 | $611,000 | $351,000 | $3M | $10M | $32M | -$252M |
| Net income | -$271M | -$289M | -$245M | -$235M | -$282M | -$168M | -$216M | -$61M | $226M | $391M |
| EPS (diluted) | -$2.34 | -$2.36 | -$1.94 | -$1.60 | -$1.79 | -$1.05 | -$1.34 | -$0.37 | $1.36 | $2.30 |
| Diluted shares | 116M | 123M | 127M | 147M | 157M | 160M | 162M | 164M | 166M | 170M |
| Gross margin | 82.2% | 92.7% | 94.5% | 96.7% | 97.7% | 97.8% | 98.0% | 94.3% | 91.5% | 91.7% |
| Operating margin | -1574.1% | -234.1% | -110.6% | -72.7% | -64.9% | -35.2% | -43.2% | -10.1% | 24.1% | 9.8% |
| Net margin | -1565.9% | -231.7% | -109.6% | -69.4% | -63.7% | -34.7% | -41.8% | -8.4% | 23.6% | 36.5% |
Balance sheet
Fiscal years, from ACADIA Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $529M | $341M | $474M | $697M | $632M | $521M | $417M | $439M | $756M | $820M |
| Receivables | $6M | $17M | $26M | $36M | $48M | $64M | $62M | $98M | $99M | $121M |
| Inventory | $4M | $5M | $4M | $6M | $10M | $14M | $12M | $40M | $92M | $111M |
| Total current assets | $548M | $373M | $526M | $760M | $718M | $618M | $508M | $616M | $938M | $1.1B |
| Property, plant and equipment | $3M | $3M | $3M | $3M | $9M | $8M | $6M | $5M | $4M | $8M |
| Total assets | $561M | $385M | $540M | $783M | $783M | $700M | $588M | $749M | $1.2B | $1.6B |
| Total current liabilities | $43M | $49M | $60M | $75M | $106M | $96M | $126M | $254M | $395M | $277M |
| Total liabilities | $43M | $49M | $61M | $84M | $156M | $159M | $187M | $317M | $455M | $337M |
| Shareholders' equity | $518M | $335M | $479M | $699M | $627M | $541M | $400M | $432M | $733M | $1.2B |
| Net debt | -$164M | -$69M | -$135M | -$190M | -$326M | -$147M | -$115M | -$189M | -$320M | -$178M |
Cash flow
Fiscal years, from ACADIA Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$208M | -$218M | -$167M | -$151M | -$136M | -$126M | -$114M | $17M | $158M | $110M |
| Capital spending | $2M | $812,000 | $2M | $1M | $8M | $1M | $0 | $50,000 | $523,000 | $5M |
| Free cash flow | -$210M | -$219M | -$170M | -$152M | -$144M | -$127M | -$114M | $17M | $157M | $105M |
| Stock-based compensation | $55M | $76M | $82M | $82M | $84M | $64M | $68M | $66M | $67M | $52M |
| Free cash flow margin | -1211.2% | -175.0% | -75.8% | -44.9% | -32.5% | -26.2% | -22.0% | 2.3% | 16.4% | 9.8% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ACAD.
Open ACAD in InvestinglyQuestions
What was ACADIA Pharmaceuticals's revenue in 2025?
$1.1B in fiscal 2025, from its 10-K filing.
How much free cash flow does ACADIA Pharmaceuticals generate?
$105M in fiscal 2025 (operating cash flow minus capital spending).
From ACADIA Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.